Epilepsy Drugs Market

Market Overview:

The global epilepsy drugs market size reached US$ 2.16 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.52 Billion by 2028, exhibiting a growth rate (CAGR) of 8.2% during 2023-2028. The rising prevalence of epilepsy, increasing incidences of brain cancer in the geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market.

Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.

At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.

Key Market Segmentation: 

IMARC Group provides an analysis of the key trends in each segment of the global epilepsy drugs market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on generation type, anti-epileptics drugs type and distribution channel. 

Generation Type Insights 

• First Generation Drugs
  • Phenytoin
  • Carbamazepine
  • Oxcarbazepine
  • Valproate
  • Ethosuximide
  • Primidone
  • Phenobarbital
• Second Generation Drugs
  • Levetiracetam
  • Lamotrigine
  • Topiramate
  • Pregabalin
  • Rufinamide
  • Zonisamide
• Third Generation Drugs
  • Lacosamide
  • Perampanel
  • Eslicarbazepine Acetate
  • Ezogabine/Retigabine
     

The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.

Anti-Epileptics Drugs Type Insights

• Narrow-Spectrum AEDs 
• Broad-Spectrum AEDs
   

A detailed breakup and analysis of the epilepsy drugs market based on the anti-epileptics drugs type has also been provided in the report. This includes narrow and broad-spectrum AEDs. According to the report, broad-spectrum AEDs accounted for the largest market share.

Distribution Channel Insights

• Hospital Pharmacy
• Pharmacy Stores
• Others
   

A detailed breakup and analysis of the epilepsy drugs market based on the distribution channel has been provided in the report. This includes hospital pharmacy, pharmacy stores, and others. According to the report, hospital pharmacy accounted for the largest market share.

Regional Insights:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.

Competitive Landscape 

The report has also provided a comprehensive analysis of the competitive landscape in the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Coverage:

Key Questions Answered in This Report: 

• How has the global epilepsy drugs market performed so far and how will it perform in the coming years? 
• What are the drivers, restraints, and opportunities in the global epilepsy drugs market? 
• What are the key regional markets? 
• Which countries represent the most attractive epilepsy drugs markets? 
• What is the breakup of the market based on the generation type? 
• What is the breakup of the market based on the anti-epileptics drugs type?  
• What is the breakup of the market based on the distribution channel?
• What is the competitive structure of the global epilepsy drugs market? 
• Who are the key players/companies in the global epilepsy drugs market? 
   

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the epilepsy drugs market from 2017-2028.  
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global epilepsy drugs market.  
• The study maps the leading as well as the fastest growing regional markets. It further enables stakeholders to identify the key country-level markets within each region. 
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the epilepsy drugs industry and its attractiveness. 
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.